Maladaptive cardiac remodeling, driven by persistent inflammation and interstitial fibrosis, remains a primary obstacle in treating heart failure (HF). While systemic anti-inflammatories have shown modest efficacy, their clinical utility is frequently limited by non-specific immunosuppression and transient therapeutic effects. To address these gaps, researchers have developed immunosuppressive chimeric antigen receptor dendritic cells (iCDCs) designed to selectively reprogram the cardiac immune microenvironment.

Equipped with a FAP-specific scFv for lesion-targeted delivery, these iCDCs constitutively express CTLA4-Ig, PD-L1, and IL-10 to promote stable, localized immune tolerance. In non-human primate (NHP) models of myocardial infarction, iCDC therapy significantly reduced infarct size and fibrosis while improving contractile function and neovascularization. Unlike systemic biologics, iCDCs leverage the endogenous cardiac antigen pool to drive durable regulatory T cell (Treg) expansion without compromising systemic immunity. Moving forward, translational efforts are focusing on ongoing clinical trials for ischemic and dilated cardiomyopathy. Future research will prioritize larger, long-term studies to define the arrhythmic safety profile and extended pharmacokinetics of the iCDC platform.

Standard-of-care treatments for idiopathic pulmonary fibrosis (IPF), specifically oral pirfenidone and nintedanib, are frequently limited by systemic side effects that hinder optimal dosing and patient adherence. Avalyn Pharma is addressing this clinical gap by developing inhaled formulations designed to maximize local drug concentration in the lungs while minimizing systemic exposure.

The company’s lead candidate, AP01 (inhaled pirfenidone), is currently undergoing a Phase IIb study (NCT06329401) for progressive pulmonary fibrosis, with a transition to Phase III trials anticipated following its IPO. The pipeline also includes AP02 (inhaled nintedanib) and AP03, a preclinical combination of both agents. AP03 specifically aims to overcome the additive toxicities that have historically precluded the oral co-administration of these drugs. Entering 2026 with USD $138M in liquidity, Avalyn is strategically positioned to advance these next-generation respiratory assets into pivotal trials as the biotech IPO market demonstrates renewed momentum.

China’s National Medical Products Administration (NMPA) has granted approval for Exdensur, an ultralong-acting biologic, as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). This indication applies to patients whose disease remains inadequately controlled by systemic corticosteroids or surgical intervention. The decision follows the recent NMPA approval of the agent for severe eosinophilic asthma, further establishing its role in managing type 2 inflammatory conditions.

Data from the Anchor-1 and Anchor-2 trials supported the approval, demonstrating statistically significant improvements in nasal polyp scores at week 52 and enhanced scores on the nasal obstruction verbal response scale. Safety profiles were comparable to placebo. Given that approximately 80% of CRSwNP cases involve underlying type 2 inflammation, Exdensur’s sustained suppression mechanism addresses a high unmet need for the nearly 50% of patients who remain uncontrolled on standard-of-care steroids. Future efforts will likely focus on real-world clinical integration within the Chinese market to complement its established presence in Japan, Europe, and the U.K.

For 20 years, Prix Galien USA has honored the breakthroughs shaping the future of healthcare and improving lives worldwide. Often regarded by the industry as the equivalent of the Nobel Prize of biopharmaceutical research, this is where innovation meets impact.

From groundbreaking therapies to life-saving technologies, this is more than an event, it’s a global movement advancing human health.

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations leading up to the event.

Takeda has terminated its research collaboration with Veritas In Silico (VIS), concluding a three-year effort to discover small molecules targeting mRNA. The partnership utilized VIS’s proprietary ibVIS platform, which identifies druggable motifs within mRNA secondary and tertiary structures, targets typically reserved for antisense oligonucleotides or siRNAs. While Takeda cited "concrete learnings" from the joint research, the decision to end the pact follows the company’s broader USD $1.3B restructuring initiative, which has recently seen Takeda exit cell therapy and terminate several neuro-focused partnerships.

Although specific drug candidates were not disclosed, the termination was described as amicable, with both firms retaining access to the generated data for potential future applications. For the biotech sector, this exit underscores Takeda’s rigorous portfolio rationalization and a shift in R&D resources toward high-priority assets, even as interest in the mRNA-targeting small molecule space remains a significant, albeit technically challenging, frontier in drug discovery.

Europe is currently navigating a significant erosion of its pharmaceutical competitiveness, increasingly squeezed by protectionist U.S. pricing models and China’s rapid emergence as a biotech leader. Europe’s share of global R&D has declined from nearly 50% in 1990 to approximately 26% today, whereas the U.S. share has expanded to 55%. This disparity is compounded by the U.S. administration's Most-Favored-Nation (MFN) pricing, which pressures manufacturers to align U.S. drug prices with the lowest international benchmarks, potentially incentivizing delayed launches in European markets to protect U.S. margins.

“Europe's pharma industry is facing a "competitiveness pincer", losing R&D share to both U.S. capital and Chinese agility. Fragmented regulation and aggressive price-capping under the MFN model threaten to turn the continent into a secondary launch market. The industry's survival may require urgent consolidation of capital markets and a shift from volume-based to value-based reimbursement."

Nimit Mistry and others